Therapeutic Tumor Infiltrating Lymphocytes: all 43 studies that test it

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte TherapyNot yet recruitingNCT07628894Phase 1
• TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and MeningiomasRecruitingNCT06640582Phase 1/2
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerRecruitingNCT06538012Phase 1/2
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerRecruitingNCT06532812Phase 1/2
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerRecruitingNCT06532799Phase 1/2
• Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum CancerRecruitingNCT06530303Phase 1/2
• Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingNCT06047977Phase 1
• E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersRecruitingNCT05686226Phase 2
• Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingNCT05681780Phase 1
• TIL Cells for the Treatment of the Advanced Solid Tumors PatientsNot yet recruitingNCT05649618Early Phase 1
• E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersRecruitingNCT05639972Phase 1/2
• Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILSRecruitingNCT05451784Phase 1/2
• A Study of GC101 TIL in Advanced Breast Cancer (10hospital)RecruitingNCT05142475Early Phase 1
• A Clinical Study on TIL for the Treatment of Advanced Solid TumorsRecruitingNCT05087745Early Phase 1
• A Study of GC101 TIL in Advanced Solid Tumors (TR)RecruitingNCT04967833Early Phase 1
• A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)RecruitingNCT04960072Early Phase 1
• Study of GC101 TIL in Brain Glioma (Soochow2)RecruitingNCT04943913Early Phase 1
• Study on TIL for the Treatment of r/r Gynecologic TumorsRecruitingNCT04766320Phase 1
• Immunotherapy for the Treatment of Advanced Solid TumorRecruitingNCT03658785Phase 1/2
• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingNCT02133196Phase 2
• TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian CancerCompletedNCT03287674Phase 1/2Results posted
• TIL Therapy for Metastatic Renal Cell CarcinomaCompletedNCT02926053Phase 1Results posted
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results posted
• Peginterferon and TIL Therapy for Metastatic MelanomaCompletedNCT02379195Phase 1/2Results posted
• A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic MelanomasTerminatedNCT02375984Phase 2Results posted
• Vemurafenib and TIL Therapy for Metastatic MelanomaCompletedNCT02354690Phase 1/2Results posted
• Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic MelanomaCompletedNCT01807182Phase 2Results posted
• Modified Tumor Infiltrating Lymphocytes for Metastatic MelanomaTerminatedNCT01369875Phase 2Results posted
• Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic MelanomaTerminatedNCT00863330Phase 2Results posted
• TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of MelanomaActive, not recruitingNCT06961786Phase 1
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWithdrawnNCT06626256Phase 1
• The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.Status unknownNCT05333588Early Phase 1
• TILs for Treatment of Metastatic or Recurrent Cervical CancerStatus unknownNCT04674488Early Phase 1
• A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic EngineeringCompletedNCT04426669Phase 1/2
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 2
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract CancersActive, not recruitingNCT03801083Phase 2
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal MelanomaActive, not recruitingNCT03467516Phase 2
• Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma MultiformeStatus unknownNCT03347097Early Phase 1
• TIL Therapy for Metastatic Ovarian CancerCompletedNCT02482090Phase 1
• Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With MelanomaCompletedNCT01883323Phase 2
• A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid TumorsStatus unknownNCT01462903Phase 1
• Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting ChemotherapyStatus unknownNCT00604136Phase 2
• Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00003665Phase 1

← Therapeutic Tumor Infiltrating Lymphocytes overview